Prostate Cancer - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 1596
Price:
US$ 2,500.00 US$ 2,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P46CFD7A590EN
Leaflet:

Download PDF Leaflet

Prostate Cancer - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Prostate Cancer - Pipeline Review, H2 2015’, provides an overview of the Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Prostate Cancer Overview
Therapeutics Development
Prostate Cancer - Therapeutics under Development by Companies
Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
Prostate Cancer - Pipeline Products Glance
Prostate Cancer - Products under Development by Companies
Prostate Cancer - Products under Investigation by Universities/Institutes
Prostate Cancer - Companies Involved in Therapeutics Development
Prostate Cancer - Therapeutics Assessment
Drug Profiles
Prostate Cancer - Recent Pipeline Updates 1138
Prostate Cancer - Dormant Projects 1483
Prostate Cancer - Discontinued Products 1522
Prostate Cancer - Product Development Milestones 1530
Appendix 1536

LIST OF TABLES

Number of Products under Development for Prostate Cancer, H2 2015
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Development by Companies, H2 2015 (Contd..11)
Number of Products under Development by Companies, H2 2015 (Contd..12)
Number of Products under Development by Companies, H2 2015 (Contd..13)
Number of Products under Development by Companies, H2 2015 (Contd..14)
Number of Products under Development by Companies, H2 2015 (Contd..15)
Number of Products under Development by Companies, H2 2015 (Contd..16)
Number of Products under Development by Companies, H2 2015 (Contd..17)
Number of Products under Development by Companies, H2 2015 (Contd..18)
Number of Products under Development by Companies, H2 2015 (Contd..19)
Number of Products under Development by Companies, H2 2015 (Contd..20)
Number of Products under Development by Companies, H2 2015 (Contd..21)
Number of Products under Investigation by Universities/Institutes, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Development by Companies, H2 2015 (Contd..14)
Products under Development by Companies, H2 2015 (Contd..15)
Products under Development by Companies, H2 2015 (Contd..16)
Products under Development by Companies, H2 2015 (Contd..17)
Products under Development by Companies, H2 2015 (Contd..18)
Products under Development by Companies, H2 2015 (Contd..19)
Products under Development by Companies, H2 2015 (Contd..20)
Products under Development by Companies, H2 2015 (Contd..21)
Products under Development by Companies, H2 2015 (Contd..22)
Products under Development by Companies, H2 2015 (Contd..23)
Products under Development by Companies, H2 2015 (Contd..24)
Products under Development by Companies, H2 2015 (Contd..25)
Products under Development by Companies, H2 2015 (Contd..26)
Products under Development by Companies, H2 2015 (Contd..27)
Products under Development by Companies, H2 2015 (Contd..28)
Products under Development by Companies, H2 2015 (Contd..29)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5)
Prostate Cancer - Pipeline by 4SC AG, H2 2015
Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015
Prostate Cancer - Pipeline by AB Science SA, H2 2015
Prostate Cancer - Pipeline by AbbVie Inc., H2 2015
Prostate Cancer - Pipeline by Acino Pharma AG, H2 2015
Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2015
Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H2 2015
Prostate Cancer - Pipeline by Aduro BioTech, Inc., H2 2015
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2015
Prostate Cancer - Pipeline by Advantagene, Inc., H2 2015
Prostate Cancer - Pipeline by Advaxis, Inc., H2 2015
Prostate Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H2 2015
Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Akshaya Bio Inc., H2 2015
Prostate Cancer - Pipeline by Alchemia Limited, H2 2015
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2015
Prostate Cancer - Pipeline by Almac Discovery Limited, H2 2015
Prostate Cancer - Pipeline by Ambrx, Inc., H2 2015
Prostate Cancer - Pipeline by Amgen Inc., H2 2015
Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H2 2015
Prostate Cancer - Pipeline by AndroScience Corporation, H2 2015
Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2015
Prostate Cancer - Pipeline by Angion Biomedica Corp., H2 2015
Prostate Cancer - Pipeline by AntiCancer, Inc., H2 2015
Prostate Cancer - Pipeline by Antigen Express, Inc., H2 2015
Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H2 2015
Prostate Cancer - Pipeline by Aphios Corporation, H2 2015
Prostate Cancer - Pipeline by APIM Therapeutics AS, H2 2015
Prostate Cancer - Pipeline by Aptose Biosciences Inc., H2 2015
Prostate Cancer - Pipeline by Armour Therapeutics Inc., H2 2015
Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by ArQule, Inc., H2 2015
Prostate Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
Prostate Cancer - Pipeline by Arrowhead Research Corporation, H2 2015
Prostate Cancer - Pipeline by Arvinas, Inc., H2 2015
Prostate Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2015
Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by AstraZeneca Plc, H2 2015
Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2015
Prostate Cancer - Pipeline by Avidity NanoMedicines, LLC, H2 2015
Prostate Cancer - Pipeline by Avipep Pty Ltd, H2 2015
Prostate Cancer - Pipeline by Axelar AB, H2 2015
Prostate Cancer - Pipeline by Azaya Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2015
Prostate Cancer - Pipeline by Baxalta Incorporated, H2 2015
Prostate Cancer - Pipeline by Bayer AG, H2 2015
Prostate Cancer - Pipeline by Beta Pharma, Inc., H2 2015
Prostate Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H2 2015
Prostate Cancer - Pipeline by BHR Pharma, LLC, H2 2015
Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H2 2015
Prostate Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2015
Prostate Cancer - Pipeline by Bionature E.A. Ltd., H2 2015
Prostate Cancer - Pipeline by Biotest AG, H2 2015
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by Blirt S.A., H2 2015
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
Prostate Cancer - Pipeline by Camurus AB, H2 2015
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Prostate Cancer - Pipeline by Cantex Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by Celgene Corporation, H2 2015
Prostate Cancer - Pipeline by CellCentric Ltd, H2 2015
Prostate Cancer - Pipeline by Cellceutix Corporation, H2 2015
Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Cellectar Biosciences, Inc., H2 2015
Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H2 2015
Prostate Cancer - Pipeline by Champions Oncology, Inc., H2 2015
Prostate Cancer - Pipeline by CohBar, Inc., H2 2015
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2015
Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Prostate Cancer - Pipeline by Crescendo Biologics Limited, H2 2015
Prostate Cancer - Pipeline by CureVac GmbH, H2 2015
Prostate Cancer - Pipeline by CytoVac A/S, H2 2015
Prostate Cancer - Pipeline by CZ BioMed Corp, H2 2015
Prostate Cancer - Pipeline by DEKK-TEC, Inc., H2 2015
Prostate Cancer - Pipeline by DexTech Medical AB, H2 2015
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
Prostate Cancer - Pipeline by DormaTarg, Inc., H2 2015
Prostate Cancer - Pipeline by Eisai Co., Ltd., H2 2015
Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2015
Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2015
Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H2 2015
Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H2 2015
Prostate Cancer - Pipeline by EndoCeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Endocyte, Inc., H2 2015
Prostate Cancer - Pipeline by EntreChem, S.L., H2 2015
Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H2 2015
Prostate Cancer - Pipeline by Erytech Pharma SA, H2 2015
Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by ESSA Pharma Inc, H2 2015
Prostate Cancer - Pipeline by Eureka Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Evgen Pharma PLC, H2 2015
Prostate Cancer - Pipeline by Exonate Limited, H2 2015
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Prostate Cancer - Pipeline by Ferring International Center S.A., H2 2015
Prostate Cancer - Pipeline by Forendo Pharma Limited, H2 2015
Prostate Cancer - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015
Prostate Cancer - Pipeline by Fortress Biotech, Inc., H2 2015
Prostate Cancer - Pipeline by Fountain Biopharma Inc., H2 2015
Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2015
Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Galileo Research s.r.l., H2 2015
Prostate Cancer - Pipeline by Genelux Corporation, H2 2015
Prostate Cancer - Pipeline by Genentech, Inc., H2 2015
Prostate Cancer - Pipeline by Genmab A/S, H2 2015
Prostate Cancer - Pipeline by GenSpera, Inc., H2 2015
Prostate Cancer - Pipeline by Gilead Sciences, Inc., H2 2015
Prostate Cancer - Pipeline by Glactone Pharma AB, H2 2015
Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015
Prostate Cancer - Pipeline by GlycoMimetics, Inc., H2 2015
Prostate Cancer - Pipeline by GP Pharm, S.A., H2 2015
Prostate Cancer - Pipeline by GTx, Inc., H2 2015
Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2015
Prostate Cancer - Pipeline by Humanetics Corporation, H2 2015
Prostate Cancer - Pipeline by Huperion Sarl, H2 2015
Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2015
Prostate Cancer - Pipeline by IC-MedTech, Inc., H2 2015
Prostate Cancer - Pipeline by IGF Oncology, LLC., H2 2015
Prostate Cancer - Pipeline by Ignyta, Inc., H2 2015
Prostate Cancer - Pipeline by Immuneed AB, H2 2015
Prostate Cancer - Pipeline by Immunocore Limited, H2 2015
Prostate Cancer - Pipeline by ImmunoFrontier, Inc., H2 2015
Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2015
Prostate Cancer - Pipeline by Immunovaccine, Inc., H2 2015
Prostate Cancer - Pipeline by Incanthera Ltd., H2 2015
Prostate Cancer - Pipeline by Incuron, LLC, H2 2015
Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2 2015
Prostate Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by Io Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Ipsen S.A., H2 2015
Prostate Cancer - Pipeline by Johnson & Johnson, H2 2015
Prostate Cancer - Pipeline by Jyant Technologies, Inc., H2 2015
Prostate Cancer - Pipeline by KAEL-GemVax Co., Ltd., H2 2015
Prostate Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H2 2015
Prostate Cancer - Pipeline by Kancera AB, H2 2015
Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2015
Prostate Cancer - Pipeline by Kite Pharma, Inc., H2 2015
Prostate Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
Prostate Cancer - Pipeline by Kura Oncology, Inc., H2 2015
Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015
Prostate Cancer - Pipeline by Lidds AB, H2 2015
Prostate Cancer - Pipeline by Luye Pharma Group Ltd., H2 2015
Prostate Cancer - Pipeline by MacroGenics, Inc., H2 2015
Prostate Cancer - Pipeline by Meabco A/S, H2 2015
Prostate Cancer - Pipeline by Mebiopharm Co., Ltd., H2 2015

LIST OF FIGURES

Number of Products under Development for Prostate Cancer, H2 2015
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc.
Acino Pharma AG
Actinium Pharmaceuticals, Inc.
Adamis Pharmaceuticals Corporation
ADC Therapeutics Sarl
Aduro BioTech, Inc.
Advanced Cancer Therapeutics
Advantagene, Inc.
Advaxis, Inc.
Aeglea BioTherapeutics, Inc.
Aeterna Zentaris Inc.
Aileron Therapeutics, Inc.
Akshaya Bio Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Ambrx, Inc.
Amgen Inc.
Anavex Life Sciences Corp.
AndroScience Corporation
AnGes MG, Inc.
Angion Biomedica Corp.
AntiCancer, Inc.
Antigen Express, Inc.
Antisense Therapeutics Limited
Aphios Corporation
APIM Therapeutics AS
Aptose Biosciences Inc.
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
Arrien Pharmaceuticals, LLC
Arrowhead Research Corporation
Arvinas, Inc.
Ascenta Therapeutics, Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
ATLAB Pharma SAS
Avidity NanoMedicines, LLC
Avipep Pty Ltd
Axelar AB
Azaya Therapeutics, Inc.
Bavarian Nordic A/S
Baxalta Incorporated
Bayer AG
Beta Pharma, Inc.
Bexion Pharmaceuticals, LLC.
BHR Pharma, LLC
BIND Therapeutics, Inc.
Bio-Cancer Treatment International Limited
Bio-Path Holdings, Inc.
Bionature E.A. Ltd.
Biotest AG
Biscayne Pharmaceuticals, Inc.
Blirt S.A.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Camurus AB
Can-Fite BioPharma Ltd.
Cantex Pharmaceuticals, Inc.
Celgene Corporation
CellCentric Ltd
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Chamaeleo Pharma NV
Champions Oncology, Inc.
CohBar, Inc.
Colby Pharmaceutical Company
Corcept Therapeutics Incorporated
Crescendo Biologics Limited
CureVac GmbH
CytoVac A/S
CZ BioMed Corp
DEKK-TEC, Inc.
DexTech Medical AB
Dongkook Pharmaceutical Co., Ltd.
DormaTarg, Inc.
Eisai Co., Ltd.
Eli Lilly and Company
Emergent BioSolutions Inc.
Enceladus Pharmaceuticals BV
Endo Pharmaceuticals Inc.
EndoCeutics, Inc.
Endocyte, Inc.
EntreChem, S.L.
Errant Gene Therapeutics, LLC
Erytech Pharma SA
Esperance Pharmaceuticals, Inc.
ESSA Pharma Inc
Eureka Therapeutics, Inc.
Evgen Pharma PLC
Exonate Limited
F. Hoffmann-La Roche Ltd.
Ferring International Center S.A.
Forendo Pharma Limited
Foresee Pharmaceuticals, LLC
Fortress Biotech, Inc.
Fountain Biopharma Inc.
Fujifilm Corporation
G1 Therapeutics, Inc.
Galectin Therapeutics, Inc.
Galileo Research s.r.l.
Genelux Corporation
Genentech, Inc.
Genmab A/S
GenSpera, Inc.
Gilead Sciences, Inc.
Glactone Pharma AB
GlaxoSmithKline Plc
GlycoMimetics, Inc.
GP Pharm, S.A.
GTx, Inc.
Hadasit Medical Research Services & Development Ltd
Humanetics Corporation
Huperion Sarl
Hybrigenics S.A.
IC-MedTech, Inc.
IGF Oncology, LLC.
Ignyta, Inc.
Immuneed AB
Immunocore Limited
ImmunoFrontier, Inc.
Immunomedics, Inc.
Immunovaccine, Inc.
Incanthera Ltd.
Incuron, LLC
Innate Immunotherapeutics Ltd
Inovio Pharmaceuticals, Inc.
Io Therapeutics, Inc.
Ipsen S.A.
Johnson & Johnson
Jyant Technologies, Inc.
KAEL-GemVax Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Kancera AB
Karyopharm Therapeutics, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Kura Oncology, Inc.
Kyowa Hakko Kirin Co., Ltd.
Lidds AB
Luye Pharma Group Ltd.
MacroGenics, Inc.
Meabco A/S
Mebiopharm Co., Ltd.
MediaPharma s.r.l.
MediGene AG
Mediolanum farmaceutici S.p.A.
Medivation, Inc.
MEI Pharma, Inc.
Merck & Co., Inc.
Merck KGaA
Merrion Pharmaceuticals Plc
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
MolMed S.p.A.
Monopar Therapeutics LLC
Morphotek, Inc.
NewLink Genetics Corporation
NormOxys, Inc.
Novartis AG
Novogen Limited
Nymox Pharmaceutical Corporation
Oasmia Pharmaceutical AB
Omeros Corporation
Omnitura Therapeutics Inc.
OncBioMune Pharmaceuticals Inc.
Oncodrone BV
Oncogenex Pharmaceuticals, Inc.
Oncolix, Inc.
Oncology Research International Limited
Oncolytics Biotech Inc.
OncoMax
OncoNOx ApS
Oncothyreon Inc.
Oncovir, Inc.
OncoVista Innovative Therapies, Inc.
Onyx Pharmaceuticals, Inc.
ORCA Therapeutics B.V.
Orion Oyj
Orphagen Pharmaceuticals, Inc.
Otsuka Holdings Co., Ltd.
OXiGENE, Inc.
Panacela Labs, Inc.
Pantarhei Bioscience BV
PDS Biotechnology Corporation
Peptron, Inc.
Pfizer Inc.
Pharmedartis GmbH
Pharmicell Co., Ltd.
Pharminox Limited
Polaris Pharmaceuticals, Inc.
Polyplus-Transfection SA
Prima BioMed Ltd.
Progenics Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Provenance Biopharmaceuticals Corp.
PSites Pharma GmbH
Qu Biologics Inc.
Quest PharmaTech Inc.
RedHill Biopharma Ltd.
RestorGenex Corporation
Rexahn Pharmaceuticals, Inc.
Rigontec GmbH
Sanofi
Sareum Holdings Plc
SEEK Group
Serometrix, LLC
Shenogen Pharma Group Ltd.
Sophiris Bio, Inc.
Soricimed Biopharma Inc.
Sorrento Therapeutics, Inc.
Sotio a.s.
Stemline Therapeutics, Inc.
Sun Pharma Advanced Research Company Ltd.
Sunesis Pharmaceuticals, Inc.
Supratek Pharma Inc.
Synta Pharmaceuticals Corp.
TaiGen Biotechnology Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Takeda Pharmaceutical Company Limited
Takis S.r.l.
Targovax AS
Tesaro, Inc.
Teva Pharmaceutical Industries Limited
Theravectys SA
TheRyte Limited
Tokai Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
TRACON Pharmaceuticals, Inc.
TREAT U, S.A.
TVAX Biomedical, Inc.
TyrNovo Ltd.
Ultimovacs AS
Vaccibody AS
ValiRx Plc
Vasgen Limited
Vaxeal Holding SA
Vaxon Biotech
Vicore Pharma AB
Vicus Therapeutics, LLC
Viralytics Ltd.
ViraTherapeutics GmbH
WntResearch AB
Yungjin Pharm. Co., Ltd.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Zymeworks Inc.
Skip to top


Ureter Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 103 pages
Rectal Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 112 pages
Thymus Cancer - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 109 pages
Uterine Cancer - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 50 pages

Ask Your Question

Prostate Cancer - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: